ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
VanEck Biotech ETF
232.02
+2.63
1.15%
盤後：
231.90
-0.1227
-0.05%
19:30 EDT
成交量：
4,581
成交額：
105.91萬
市值：
4.66億
市盈率：
- -
高：
232.10
開：
230.06
低：
229.59
收：
229.39
52周最高：
244.35
52周最低：
160.91
股本：
200.65萬
流通股本：
200.65萬
量比：
0.48
換手率：
0.23%
股息：
0.95
股息率：
0.41%
淨資產收益率：
--
總資產收益率：
--
市淨率：
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
安進（AMGN）降脂藥Repatha新臨床數據：可降低未發生心梗或中風高危患者20%死亡風險
金吾财讯
·
08/31
美國FDA批准胰腺癌突破性藥物 獨立藥企Revolution Medicines迎里程碑
环球市场播报
·
08/28
美國食品藥品監督管理局（FDA）批准吉利德治療艾滋病的每日一次複方片劑
路透中文
·
08/28
美國FDA批准吉利德科學Bixlenvo™上市：每日單片方案為病毒學抑制HIV成人患者提供新選擇，涵蓋複雜治療方案人群
美股速递
·
08/28
Street View：Revolution的胰腺癌藥物獲批，開啓「變革性」時代
路透中文
·
08/27
英國股市——8月27日需關注的因素
路透中文
·
08/27
阿斯利康的哮喘藥物Tezspire在食管炎晚期臨床試驗中達到了所有目標
路透中文
·
08/27
Tezspire®在嗜酸性食管炎III期臨床試驗中展現積極成果，共同主要終點及所有關鍵次要終點全面達標
美股速递
·
08/27
傑富瑞：將Revolution Medicines目標價從242美元上調至270美元。
智通财经
·
08/27
Revolution Medicines旗下Rasonque美國正式上市，30天療程批發採購價39,800美元——電話會議披露
美股速递
·
08/27
美國FDA批准Revolution Medicines旗下Rasonque™（Daraxonrasib）上市，開創轉移性胰腺癌廣譜Ras靶向治療先河
美股速递
·
08/27
BUZZ——美國股市動態-Revolution Medicines、Abercrombie & Fitch、Williams-Sonoma
路透中文
·
08/26
Revolution Medicines的胰腺癌藥物 Daraxonrasib已獲得美國監管機構的批准，這是首款針對胰腺
智通财经
·
08/26
美國食品藥品監督管理局（FDA）批准了Revolution Medicines公司的一款胰腺癌藥物
路透中文
·
08/26
歐盟委員會擴大吉利德Trodelvy®在轉移性三陰性乳腺癌一線治療中的應用範圍，覆蓋所有PD-L1狀態
美股速递
·
08/24
吉利德科學：歐盟批准Trodelvy聯合Keytruda用於一線PD-L1陽性轉移性三陰性乳腺癌
美股速递
·
08/24
美國聯邦貿易委員會（FTC）：安進專利申請收購交易受到反壟斷審查。
智通财经
·
08/21
Piper Sandler上調安進目標價至457美元
格隆汇
·
08/21
美國研究綜述-安進、Analog Devices、莫德納
路透中文
·
08/20
福泰製藥(VRTX)股票8月19日收盤上漲4.48%：釋放什麼信號？
TradingKey中文
·
08/20
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BBH/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BBH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","market":"US","secType":"STK","nameCN":"VanEck Biotech ETF","latestPrice":232.024,"timestamp":1789416000000,"preClose":229.3922,"halted":0,"volume":4581,"hourTrading":{"tag":"盘后","latestPrice":231.9013,"preClose":232.024,"latestTime":"19:30 EDT","volume":18,"amount":4175.136,"timestamp":1789428602348,"change":-0.1227,"changeRate":-0.000529,"amplitude":0},"delay":0,"changeRate":0.011472927152710503,"floatShares":2006503,"shares":2006503,"eps":0,"marketStatus":"未開盤","change":2.6318,"latestTime":"09-14 16:00:00 EDT","open":230.06,"high":232.1,"low":229.5938,"amount":1059133.20111,"amplitude":0.010925,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":229.3922,"sharesOutstanding":1976503,"nav":229.3061,"aum":460103384.52,"dividendRate":0.0041,"bidAskSpread":0.001038,"postHourTrading":{"tag":"盘后","latestPrice":231.9013,"preClose":232.024,"latestTime":"19:30 EDT","volume":18,"amount":4175.136,"timestamp":1789428602348,"change":-0.1227,"changeRate":-0.000529,"amplitude":0},"volumeRatio":0.482698,"impliedVol":0.187,"impliedVolPercentile":0.376},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","floatShares":2006503,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.482698,"shares":2006503,"dividePrice":0.9513,"high":232.1,"amplitude":0.010925,"preClose":229.3922,"low":229.5938,"week52Low":160.91,"pbRate":"--","week52High":244.345,"institutionHeld":0,"latestPrice":232.024,"eps":0,"divideRate":0.0041,"volume":4581,"delay":0,"ttmEps":0,"open":230.06,"prevYearClose":189.2649,"prevWeekClose":229.3922,"prevMonthClose":236.396,"prevQuarterClose":203.2373,"fiveDayClose":241.1222,"twentyDayClose":218.0411,"sixtyDayClose":188.0998},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBH","amount":0.9565,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-12-23","symbol":"BBH","amount":1.2517,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-24"},{"date":"2023-12-18","symbol":"BBH","amount":0.7127,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"VanEck Biotech ETF","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"BBH","amount":0.7488,"defaultRemindTime":1671460200000,"name":"VanEck Biotech ETF","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"BBH","amount":0.3972,"defaultRemindTime":1640010600000,"name":"VanEck Vectors Biotech ETF","recordDate":"2021-12-27","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-19","recordDate":"2016-12-21","paymentDate":"2016-12-23","value":0.327,"currency":"USD"},{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.006,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-30","value":0.4724,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-28","value":0.6079,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-27","value":0.3972,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBH\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663778550","title":"安進（AMGN）降脂藥Repatha新臨床數據：可降低未發生心梗或中風高危患者20%死亡風險","url":"https://stock-news.laohu8.com/highlight/detail?id=2663778550","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663778550?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 18:48","pubTimestamp":1788173287,"startTime":"0","endTime":"0","summary":"研究结果显示，对于既往未发生过心肌梗死或中风的高危成年患者，在接受他汀类或其他降脂疗法的基础上加用Repatha，可显著降低20%的全因死亡风险，同时有效降低心血管死亡率。数据显示，Repatha能在治疗开启最早6个月内降低心梗风险，且将患者低密度脂蛋白胆固醇中位数降低至45mg/dL，远优于安慰剂组的109mg/dL。此外，欧盟委员会已于2026年8月批准扩大Repatha在欧洲的适应症，用于确诊或高危确诊的动脉粥样硬化性心血管疾病成年患者降低心血管风险。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/Mjk1NzA2YjQxMDg1MTQ0MjI1MzE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Mjk1NzA2YjQxMDg1MTQ0MjI1MzE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305491","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU1983299246.USD","AMGN","BK4581","LU2468319806.SGD","LU2242646821.SGD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE0002141913.USD","LU1057294990.SGD","LU2089984988.USD","LU2112291526.USD","BIB","BK4588","LU2242652126.USD","LU1061106388.HKD","BK4566","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0058720904.USD","LU1571399168.USD","IBB","PBE","PJP","IBBQ","BBH","TBXU","IE00BJT1NW94.SGD","BK4139","LU0868494617.USD","LU1023059063.AUD","SG9999001440.SGD","BK4534","BK4599","LU0109394709.USD","LU0122379950.USD","BK4533","IE0009355771.USD","BK4585","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662061828","title":"美國FDA批准胰腺癌突破性藥物 獨立藥企Revolution Medicines迎里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662061828","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662061828?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 18:15","pubTimestamp":1787912149,"startTime":"0","endTime":"0","summary":"Revolution Medicines历时近十年持续攻关，在500人规模临床试验中获得积极数据，最终获得监管批准。为完成交易，戈德史密斯与Warp Drive最大股东赛诺菲协商，将后者持有的Warp Drive多数股权置换为Revolution Medicines的部分股权，最终达成协议。在正式获批前，美国食品药品管理局已通过同情用药项目允许Revolution Medicines提前约四个月向患者分发药物，截至获批时已有超过2000名患者纳入该项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-28/doc-inipwhrt5845666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["LABU","BBH","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","PTH","BK4588","IE00B4R5TH58.HKD","BK4585","LU0109394709.USD","IDNA","IE0009354923.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","CANC","IE0009355771.USD","IE00BJJMRZ35.SGD","RVMD","LU0889565916.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036374","title":"美國食品藥品監督管理局（FDA）批准吉利德治療艾滋病的每日一次複方片劑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036374","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036374?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 05:50","pubTimestamp":1787867453,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）批准吉利德治疗艾滋病的每日一次复方片剂路透8月27日-吉利德科学公司周四表示，美国食品和药物管理局已批准该公司研发的每日一次口服复方药GILD.O，用于治疗HIV病毒载量已降至极低水平的成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4S44O24V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3T34201.USD","TBXU","IBBQ","LU0109394709.USD","LU1037948541.HKD","BIB","BK4139","SG9999015945.SGD","LU0289739699.SGD","BK4583","BK4585","LU1023059063.AUD","LU1571399168.USD","IE00B7SZLL34.SGD","IE0002270589.USD","BK4568","LU1934455194.USD","IE00BKVL7J92.USD","LU0889565916.HKD","LU1037948897.HKD","LU2112291526.USD","BMED","LU2324357040.USD","BK4566","LU2468319806.SGD","LU1934455277.USD","SG9999015986.USD","BK4532","IE00BZ1G4Q59.USD","SG9999015978.USD","LU0058720904.USD","IBB","LU1674673691.USD","LU0965509101.SGD","BBH","LU0861579265.USD","SG9999015952.SGD","LU1839511570.USD","LU0823416689.USD","LU1430594728.SGD","LU0114720955.EUR","LU0965508806.USD","LU0965509283.SGD","TMED","LU1066053197.SGD","IE00B19Z3581.USD","GILD","MEDI","LU1778281490.HKD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198194055","title":"美國FDA批准吉利德科學Bixlenvo™上市：每日單片方案為病毒學抑制HIV成人患者提供新選擇，涵蓋複雜治療方案人群","url":"https://stock-news.laohu8.com/highlight/detail?id=1198194055","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198194055?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 05:49","pubTimestamp":1787867358,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局正式批准了吉利德科学旗下新药Bixlenvo。这款每日一次的单片制剂，专为病毒学抑制状态的HIV成人感染者设计——即便是那些正在接受复杂治疗方案的病患，也适用这一新选项。此项获批标志着HIV治疗领域又添一枚重要砝码。Bixlenvo以单片复方形式呈现，将给药频率与用药负担同步压缩，患者无需再面对繁琐的多药组合。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU2357627491.SGD","SG9999015978.USD","LU1066051498.USD","LU1934455194.USD","LU1061106388.HKD","IE00BZ1G4Q59.USD","LU1674673428.USD","TMED","SG9999015952.SGD","IBB","LU1023059063.AUD","LU0320765992.SGD","BK4583","BK4588","LU2087621335.USD","BK4585","IBBQ","LU0965509010.AUD","LU1778281490.HKD","LU0965508806.USD","LU1585245621.USD","BK4578","BK4550","IE00B19Z3581.USD","LU0823416689.USD","LU0882574055.USD","LU2089984988.USD","TBXU","LU0289739699.SGD","LU0861579265.USD","LU0965509283.SGD","IE00B7SZLL34.SGD","LU1037948541.HKD","LU1571399168.USD","LU1674673691.USD","SG9999015986.USD","IE0002270589.USD","LU0109394709.USD","LU1430594728.SGD","BK4568","LU0889565916.HKD","LU1934455277.USD","BBH","BMED","LU2112291526.USD","BIB","LU0058720904.USD","LU0859254822.USD","LU1057294990.SGD","IE00B3T34201.USD","MEDI","LU2324357040.USD","LU0114720955.EUR","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU0234570918.USD","LU0965509101.SGD","LU1037948897.HKD","IE00BSNM7G36.USD","LU1839511570.USD","LU2468319806.SGD","LU1066053197.SGD","LU1934455863.HKD","BK4532","GILD","SG9999015945.SGD","BK4139","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662704894","title":"Street View：Revolution的胰腺癌藥物獲批，開啓「變革性」時代","url":"https://stock-news.laohu8.com/highlight/detail?id=2662704894","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662704894?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 19:36","pubTimestamp":1787830591,"startTime":"0","endTime":"0","summary":"BUZZ-Street View：Revolution的胰腺癌药物获批，开启“变革性”时代8月27日-** Revolution Medicines旗下RVMD.O公司研发的、具有突破性的 胰腺癌药物Rasonque于周三获得美国FDA批准** RVMD股价盘前上涨3%，报222美元；该股平均评级为“买入”，目标价中位数为240美元——路孚特数据** 监管部门批准后，至少有7位分析师上调了目标价化疗后时代来临？","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4T44O15A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139","IE00BJJMRZ35.SGD","CANC","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE0002141913.USD","IE0009355771.USD","IDNA","IE00BJT1NW94.SGD","PTH","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","IE00BFTCPJ56.SGD","IE0009354923.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662775484","title":"英國股市——8月27日需關注的因素","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775484","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662775484?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:53","pubTimestamp":1787813617,"startTime":"0","endTime":"0","summary":"更新 1-英国股市——8月27日需关注的因素新增新闻报导，更新期货行情路透8月27日-预计周四英国富时100指数.FTSE将低开，期货FFIc1下跌0.4%。*7月汽车产量：行业数据显示，受出口疲软及部分工厂提前进行夏季检修停产影响，英国7月汽车产量 同比下降11.6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4T44O0JK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","LU1880407132.USD","LU0171276677.USD","PPH.UK","LU0963555726.SGD","LU0969580561.USD","LU0553294199.USD","LU0171293334.USD","BK5105","LU0949170426.SGD","LU1057294990.SGD","LU0868494617.USD","BBH","LU0345780950.USD","LU1267930573.SGD","BK4139","LU1104425308.USD","BIB","GLEN.UK","PBE","BK4585","TBXU","SGXZ57979304.SGD","LU0857590862.USD","LU0889565916.HKD","LU0792757196.USD","PRU.UK","LU1989771016.USD","LU1355424745.HKD","IBB","LU0075056555.USD","LU2089984988.USD","PJP","IBBQ","LU1119994496.HKD","SG9999001176.SGD","LU0122379950.USD","LU1989772923.USD","LU1267930227.SGD","LU0310800379.SGD","AZN.UK","03165","LU2293690082.USD","CRDA.UK","LU0047713382.USD","GAW.UK","HFD.UK","LU0211326755.USD","IE0034235188.USD","LU0345777147.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662639773","title":"阿斯利康的哮喘藥物Tezspire在食管炎晚期臨床試驗中達到了所有目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2662639773","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662639773?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:08","pubTimestamp":1787810905,"startTime":"0","endTime":"0","summary":"阿斯利康的哮喘药物Tezspire在食管炎晚期临床试验中达到了所有目标路透8月27日-阿斯利康（AstraZeneca）AZN.L周四表示，其与安进（Amgen）AMGN.O联合开发的哮喘药物Tezspire，在治疗嗜酸性粒细胞性食管炎（一种食管的慢性炎症性疾病）的晚期临床试验中达到了主要和次要研究目标。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4T44O0GC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU0171276677.USD","LU0640478417.SGD","PBE","LU1196032939.SGD","LU0390134368.USD","TBXU","BBH","LU0158827948.USD","LU0211328371.USD","LU0757432116.USD","LU0496365809.HKD","BK4588","AMGN","IBB","LU0203345920.USD","PJP","LU1015430645.USD","LU1064927863.SGD","IE00B2B36J28.USD","BK4139","LU1481599808.USD","LU2089284900.SGD","BK5011","LU1273509221.SGD","LU0823416689.USD","LU0889565916.HKD","LU2237443549.SGD","LU0882574055.USD","LU2357627491.SGD","LU1989772840.SGD","LU0949170426.SGD","LU1061106388.HKD","LU1323610961.USD","LU0011850046.USD","03165","LU1119994496.HKD","IBBQ","LU2125909247.SGD","AZN.UK","LU0557290698.USD","LU0211327993.USD","BIB","LU1261432733.SGD","BK4599","LU0960981461.USD","LU0432979614.USD","LU1267930813.SGD","LU1923622614.USD","LU0526926950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146489142","title":"Tezspire®在嗜酸性食管炎III期臨床試驗中展現積極成果，共同主要終點及所有關鍵次要終點全面達標","url":"https://stock-news.laohu8.com/highlight/detail?id=1146489142","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146489142?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:00","pubTimestamp":1787810443,"startTime":"0","endTime":"0","summary":"Tezspire在针对嗜酸性食管炎的III期临床试验中取得了令人瞩目的积极结果。该试验不仅成功达到了共同主要终点，而且所有关键次要终点也悉数告捷。Tezspire的优异表现，标志着该领域治疗可能迎来重大变革。共同主要终点的同时达成，以及关键次要终点的全面覆盖，充分验证了Tezspire的疗效一致性和临床获益的广泛性。业内专家指出，Tezspire的这项研究成果，不仅巩固了其在炎症性疾病治疗领域的地位，更可能为后续的监管审批和市场推广奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU0868494617.USD","BK4139","LU1571399168.USD","IE00BJT1NW94.SGD","TBXU","LU1983299246.USD","LU0289739699.SGD","BK4533","IE00BFTCPJ56.SGD","BBH","BIB","BK4534","IE00B4R5TH58.HKD","LU0122379950.USD","IE0002141913.USD","LU2089984988.USD","PBE","BK4566","IBB","BK4599","IBBQ","IE00B2B36J28.USD","LU0320765992.SGD","IE0009355771.USD","BK4585","SG9999001440.SGD","LU1057294990.SGD","LU0889565916.HKD","LU2112291526.USD","LU2242652126.USD","LU2242646821.SGD","BK4588","PJP","LU0109394709.USD","BK4581","LU0058720904.USD","LU2468319806.SGD","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662722025","title":"傑富瑞：將Revolution Medicines目標價從242美元上調至270美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662722025","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662722025?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 11:50","pubTimestamp":1787802605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CANC","IDNA","PTH","IE00B4R5TH58.HKD","UDN","UUP","BBH","IE0009355771.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE0009354923.USD","IE00BJT1NW94.SGD","LU0320765992.SGD","IE00B2B36J28.USD","LU0109394709.USD","IE0002141913.USD","RVMD","IE00BFTCPJ56.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164882019","title":"Revolution Medicines旗下Rasonque美國正式上市，30天療程批發採購價39,800美元——電話會議披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1164882019","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164882019?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 01:57","pubTimestamp":1787767031,"startTime":"0","endTime":"0","summary":"Revolution Medicines公司日前宣布，其研发的Rasonque药物现已在美国市场正式商业化供应。这款产品的批发采购成本定为39,800美元，对应30天的用药剂量。值得注意的是，此次上市定价反映了Rasonque在精准肿瘤治疗领域的差异化价值主张。从商业角度看，这一价格策略也释放出Revolution Medicines对其产品竞争力的强烈信心。分析人士指出，随着Rasonque正式进入流通渠道，相关供应链与市场准入工作已全面启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BK4139","IDNA","IE00B4R5TH58.HKD","IE0009354923.USD","LU0889565916.HKD","RVMD","IE0002141913.USD","IE00BJT1NW94.SGD","BBH","PTH","IE00BFTCPJ56.SGD","CANC","IE00B2B36J28.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156385670","title":"美國FDA批准Revolution Medicines旗下Rasonque™（Daraxonrasib）上市，開創轉移性胰腺癌廣譜Ras靶向治療先河","url":"https://stock-news.laohu8.com/highlight/detail?id=1156385670","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156385670?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 01:00","pubTimestamp":1787763644,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局正式批准了Revolution Medicines研发的Rasonque——这标志着全球首款针对转移性胰腺癌的广谱Ras靶向药物成功问世。此举不仅为晚期胰腺癌患者带来了全新的治疗选项，更在肿瘤精准医疗领域树立起一座重要的里程碑。此次获批，无疑将深刻影响胰腺癌治疗的现有格局。对于广大深受胰腺癌困扰的患者群体而言，Rasonque的上市，无疑为他们与病魔的抗争增添了一件有力武器。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","IE00BJT1NW94.SGD","LU0320765992.SGD","LU0109394709.USD","IE00BJJMRZ35.SGD","CANC","IE0009355771.USD","IE00B4R5TH58.HKD","IE0002141913.USD","BBH","BK4139","IDNA","IE00BFTCPJ56.SGD","RVMD","IE0009354923.USD","PTH","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662436927","title":"BUZZ——美國股市動態-Revolution Medicines、Abercrombie & Fitch、Williams-Sonoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2662436927","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662436927?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 23:45","pubTimestamp":1787759102,"startTime":"0","endTime":"0","summary":".N美国东部时间11:30，道琼斯工业平均指数.DJI下跌0.25%，报53,444.86点。标普500指数.SPX下跌0.02%，报7,675.90点；纳斯达克综合指数.IXIC下跌0.20%，报26,098.72点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4S44N1B5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B4R5TH58.HKD","BK4585","IE0002141913.USD","RVMD","BK4139","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0109394709.USD","PTH","BK4178","LU0942090050.USD","LU0320765992.SGD","LU0889565916.HKD","IE0009354923.USD","LU0170899867.USD","IE00B2B36J28.USD","BBH","IE00BFTCPJ56.SGD","WSM","BK4588","ANF","IDNA","LU0868494708.USD","CANC","BK4094","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662482997","title":"Revolution Medicines的胰腺癌藥物 Daraxonrasib已獲得美國監管機構的批准，這是首款針對胰腺","url":"https://stock-news.laohu8.com/highlight/detail?id=2662482997","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662482997?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 23:14","pubTimestamp":1787757271,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B2B36J28.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0320765992.SGD","BBH","RVMD","PTH","IDNA","IE0009355771.USD","CANC","IE00BJT1NW94.SGD","BK4139","IE0002141913.USD","IE0009354923.USD","IE00B4R5TH58.HKD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662271008","title":"美國食品藥品監督管理局（FDA）批准了Revolution Medicines公司的一款胰腺癌藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2662271008","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662271008?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 22:44","pubTimestamp":1787755452,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）批准了Revolution Medicines公司的一款胰腺癌药物路透8月26日-美国食品药品监督管理局周三表示，已批准Revolution Medicines公司用于治疗转移性胰腺癌的靶向药物RVMD.O。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4T44N176:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU0320765992.SGD","IE00BJJMRZ35.SGD","LU0889565916.HKD","PTH","CANC","IE00B4R5TH58.HKD","IE0009354923.USD","IE0002141913.USD","IE00BJT1NW94.SGD","LU0109394709.USD","RVMD","BK4139","IE0009355771.USD","IE00BFTCPJ56.SGD","IDNA","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186632498","title":"歐盟委員會擴大吉利德Trodelvy®在轉移性三陰性乳腺癌一線治療中的應用範圍，覆蓋所有PD-L1狀態","url":"https://stock-news.laohu8.com/highlight/detail?id=1186632498","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186632498?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 18:32","pubTimestamp":1787567559,"startTime":"0","endTime":"0","summary":"欧盟委员会近日作出重要决定，将吉利德科学（Gilead Sciences）旗下重磅药物Trodelvy®的适用范围进一步拓宽。此次调整聚焦于转移性三阴性乳腺癌的一线治疗领域，且不再受限于患者的PD-L1表达状态。这一举措意味着，无论生物标志物检测结果如何，符合条件的患者均有望从该疗法中获益。此举不仅为临床医生提供了更为灵活的用药选择，也标志着Trodelvy®在肿瘤治疗版图中的地位得到显著提升。吉利德科学方面对此表示积极回应，认为该批准将助力满足更多患者未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509283.SGD","LU1839511570.USD","GILD","LU1037948541.HKD","IE0002270589.USD","LU2357627491.SGD","LU2089984988.USD","LU1037948897.HKD","LU0889565916.HKD","BK4532","LU0289739699.SGD","IE00B19Z3B42.SGD","LU0320765992.SGD","LU1023059063.AUD","LU0058720904.USD","LU0823416689.USD","SG9999015945.SGD","LU2087621335.USD","BK4578","BK4585","LU0861579265.USD","TBXU","IE00B3T34201.USD","LU0859254822.USD","BBH","LU1430594728.SGD","LU1934455863.HKD","LU2324357040.USD","BK4139","IE00BSNM7G36.USD","LU0882574055.USD","LU1066051498.USD","LU0234570918.USD","IBBQ","IE00B7SZLL34.SGD","BK4583","BMED","LU2112291526.USD","BK4566","BIB","LU0965508806.USD","LU0965509101.SGD","BK4550","IE00B19Z3581.USD","LU1778281490.HKD","LU1057294990.SGD","LU1934455194.USD","LU1066053197.SGD","IE00BKVL7J92.USD","LU0109394709.USD","LU0965509010.AUD","SG9999015978.USD","LU0114720955.EUR","SG9999015952.SGD","IE00BZ1G4Q59.USD","BK4568","LU1674673428.USD","MEDI","IBB","LU0122379950.USD","BK4588","LU1571399168.USD","LU1585245621.USD","LU1934455277.USD","LU1674673691.USD","LU2468319806.SGD","SG9999015986.USD","TMED","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193380081","title":"吉利德科學：歐盟批准Trodelvy聯合Keytruda用於一線PD-L1陽性轉移性三陰性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1193380081","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193380081?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 18:32","pubTimestamp":1787567533,"startTime":"0","endTime":"0","summary":"吉利德科学公司宣布，欧盟已正式授予其抗体药物偶联物Trodelvy与默沙东的Keytruda联合用药方案的上市许可。这一批准针对的是既往未经治疗的PD-L1阳性转移性三阴性乳腺癌患者群体。此项授权标志着该联合疗法在欧盟地区的临床可及性迈出关键一步，为这类侵袭性强、治疗选择有限的乳腺癌亚型患者提供了新的一线治疗选项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015978.USD","IE0002270589.USD","BK4578","LU1430594728.SGD","LU0109394709.USD","LU0289739699.SGD","LU1585245621.USD","LU1934455194.USD","LU2468319806.SGD","SG9999015952.SGD","SG9999015986.USD","BMED","LU2089984988.USD","LU2357627491.SGD","LU1839511570.USD","BIB","IE00BZ1G4Q59.USD","LU0965509010.AUD","LU2112291526.USD","IE00BKVL7J92.USD","LU1037948541.HKD","IE00B19Z3B42.SGD","BK4583","LU1061106388.HKD","LU0234570918.USD","BBH","LU0320765992.SGD","TBXU","LU1934455863.HKD","MEDI","BK4532","LU1934455277.USD","LU1674673428.USD","LU0859254822.USD","LU0882574055.USD","BK4585","LU1066053197.SGD","GILD","IBB","BK4568","TMED","BK4139","IBBQ","IE00B7SZLL34.SGD","LU0889565916.HKD","LU1037948897.HKD","LU0823416689.USD","LU0965509283.SGD","LU1674673691.USD","LU0114720955.EUR","LU1023059063.AUD","LU1066051498.USD","LU0965509101.SGD","LU1571399168.USD","LU1057294990.SGD","IE00BSNM7G36.USD","LU0058720904.USD","BK4550","BK4566","LU1778281490.HKD","LU0122379950.USD","LU0861579265.USD","LU2087621335.USD","LU2324357040.USD","SG9999015945.SGD","IE00B19Z3581.USD","LU0965508806.USD","IE00B3T34201.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661291370","title":"美國聯邦貿易委員會（FTC）：安進專利申請收購交易受到反壟斷審查。","url":"https://stock-news.laohu8.com/highlight/detail?id=2661291370","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661291370?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 23:49","pubTimestamp":1787327356,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PJP","RSPT","DISC","LRGG","TBXU","QQMG","GXPC","EMQQ","BIB","BUYO","IXP","BBH","ARB","BCTK","MRGR","NBDS","ORCZ","FCOM","BWEB","TRUC","EVNT","ONEQ","FTC","WEBL","MSFX","HCA","MUSQ","PBE","GXPT","IBBQ","XLCI","JHMT","GOOX","IEME","IHF","IBB","PBS","MNA","TGRW","WEBX","CWC","AMGN","NBCC","TDAQ","JHCS","DRUP","MSFY","PNQI","KEMQ","GGTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661250489","title":"Piper Sandler上調安進目標價至457美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661250489","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661250489?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 15:20","pubTimestamp":1787296801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BBH","LU0320765992.SGD","LU2242652126.USD","IE0002141913.USD","BK4599","LU0109394709.USD","PJP","BK4534","BK4566","PBE","AMGN","LU1571399168.USD","BK4588","LU1061106388.HKD","LU0122379950.USD","LU1983299246.USD","LU1057294990.SGD","SG9999001440.SGD","IBB","LU2468319806.SGD","LU0058720904.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","BIB","BK4533","BK4585","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","LU2112291526.USD","LU1023059063.AUD","TBXU","IBBQ","BK4139","LU0289739699.SGD","UDN","UUP","BK4581","LU2242646821.SGD","IE00B4R5TH58.HKD","LU2089984988.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660043834","title":"美國研究綜述-安進、Analog Devices、莫德納","url":"https://stock-news.laohu8.com/highlight/detail?id=2660043834","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660043834?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 15:49","pubTimestamp":1787212153,"startTime":"0","endTime":"0","summary":"美国研究综述-安进、Analog Devices、莫德纳路透8月20日-周四，华尔街证券分析师上调了多家在美国上市公司的评级和目标股价，其中包括安进、模拟设备公司和莫德纳。股票按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nL4S44H0HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLOU","IE00BJJMRZ35.SGD","LU1235294995.USD","LU1057294990.SGD","LU1670711040.USD","IYH","LU2506952170.USD","IE00BDGV0183.EUR","IGV","LU2298322129.HKD","LU1064131342.USD","MRNY","LU1815336760.USD","LU0058720904.USD","SG9999000418.SGD","IE00BZ9MQY76.HKD","WISE","SG9999001176.SGD","ABBV","LU2517655028.SGD","LU1551013425.SGD","IE000M9KFDE8.USD","SG9999014039.USD","IDNA","LU0068578508.USD","LU0965508806.USD","LU2023250843.SGD","LU2322448791.USD","LU0211327993.USD","BK4599","LU0912757837.SGD","LU2458330243.SGD","LU2237443549.SGD","LU1623119135.USD","FDTX","VHT","LU1169589451.USD","IE00B1BXHZ80.USD","BK4535","LU2242646821.SGD","LU2129689514.USD","IE000F7OJYX1.SGD","BK4550","LU0320765992.SGD","LU1861214812.USD","LU1150488218.USD","SG9999015986.USD","LU2461242641.AUD","LU0081259029.USD","LU0820561818.USD","MRNX","SG9999014021.USD","LU1941712264.USD","LU0256863811.USD","MRVX","LU1839511570.USD","LU1917777945.USD","IE00B3PB1722.GBP","LU1941712348.USD","BUG","LU0158827948.USD","IE0009356076.USD","LU1093756168.USD","LU2552382058.USD","LU0661504455.SGD","LU0985320562.USD","IE0004091025.USD","LU1989763005.USD","LU0256863902.USD","LU0122379950.USD","CRWC","BK4185","GTEK","LU0690374615.EUR","LU1732800096.USD","IE00B2B36J28.USD","LU2552382215.SGD","LU1720051017.SGD","LU2298321311.HKD","SNOU","LU0417517546.SGD","CLOD","BK4501","LU2357305700.SGD","PJP","LU2092937221.SGD","BK4533","LU0130517989.USD","TRUH","LU1291159041.SGD","LU2089985449.USD","SGXZ57979304.SGD","TJX","LU0950375773.USD","LU2487616109.SGD","LU1162221912.USD","LU1267930490.SGD","MEDX","ARTY","LU0127658192.USD","BK4534","SG9999014542.SGD","LU0310799852.SGD","LU0511384066.AUD","BK4528","LU2129689431.USD","LU2023250504.SGD","IE0002270589.USD","LU1823568750.SGD","LU1023059063.AUD","LU0823417737.USD","IE00BVYPNV92.GBP","IE000WAW04H5.SGD","CIBR","BK4558","BIB","LU1989771016.USD","LU1585245621.USD","BMED","LU2360106780.USD","LU0289739343.SGD","LU1037948897.HKD","IE00B5949003.HKD","LU0943347566.SGD","LU0868494617.USD","LU0545039389.USD","BK4505","LU1046421795.USD","LGHT","LU0795875169.SGD","LU1861220033.SGD","LU2272731600.USD","LU0109394709.USD","LU1852331112.SGD","LU2244417387.USD","SG9999011175.SGD","LU2106854487.HKD","LU2125909247.SGD","LU0289739699.SGD","PAWZ","IE00BLSP4452.SGD","LU0477156953.USD","MRVL","HRTS","LU2491050071.SGD","LU1803068979.SGD","LOW","LU2433249047.HKD","SG9999002232.USD","XDAT","LU2506951958.HKD","LU0124676726.USD","LU2360107325.USD","LU2272731865.HKD","LU0456855351.SGD","LU0823421416.USD","LU1066051498.USD","LU1074936037.SGD","LU2237438978.USD","LU2458330169.SGD","IE0009355771.USD","HAKY","LU0098860793.USD","SG9999002224.SGD","LU0070302665.USD","LU1244550494.USD","BK4130","IE00BJT1NW94.SGD","IE00BSNM7G36.USD","LU1983299246.USD","LU1674673428.USD","LU2237443895.HKD","LU0689626769.HKD","LU1778281490.HKD","LU0965509101.SGD","SG9999001440.SGD","SG9999015952.SGD","LU0882574055.USD","FHLC","LU0861579265.USD","LU0395794307.EUR","IE00B19Z9Z06.USD","LU0238689110.USD","LU0823434740.USD","LU0476273544.USD","IE00BBT3K403.USD","MRVU","IE00BMPRXN33.USD","LU1169590202.USD","LU2265009873.SGD","XLV","LU2361044865.SGD","MVLL","BK4566","WDAY","LU2264538146.SGD","SG9999013999.USD","IE00BD6J9T35.USD","IE0004086264.USD","SG9999014005.SGD","IE000BZT7R73.USD","IE00B19Z9P08.USD","LU2404859667.USD","TBXU","LU0289961442.SGD","LU0642271901.SGD","BK4605","LU1934455277.USD","FAI","LU2404859741.USD","LU0077335932.USD","LU2098885051.SGD","LU0868494708.USD","EL","SNOY","SG9999015978.USD","LU1934455194.USD","LU2023251221.USD","LU2089283258.USD","BK4548","PBE","LU0689472784.USD","LU0444971666.USD","SNOW","LU0823434583.USD","LU1003077747.HKD","SG9999015341.SGD","LU2517655291.USD","MRNA","LU1861219969.SGD","BK4592","LU0965509283.SGD","LU1316542783.SGD","LU1935042991.SGD","LU0859254822.USD","IHF","LU0052756011.USD","LU2237443382.USD","IE0034235188.USD","IE0000B7K699.USD","LU2361044949.HKD","LU0130102774.USD","LU0211331839.USD","LU1989772840.SGD","BBH","LU1496350171.SGD","LU2286300806.USD","LU0823417653.USD","LU0889565833.HKD","LU1571399168.USD","LU2360107168.USD","LU1267930573.SGD","LU1992135399.USD","BK4504","WDNA","GLAM","LU1244550577.SGD","IE00BFTCPJ56.SGD","LU0061475181.USD","LU0128525929.USD","BK4598","LU2125909916.SGD","BK4581","LU2211815571.USD","LU1066051225.USD","BK4585","IE00BMPRXQ63.HKD","MRK","BK4516","IE000MB6IJN5.SGD","BK4588","SG9999015945.SGD","LU0094547139.USD","LU1974910355.USD","LU2355687059.USD","BILL","LU0302445910.USD","LU2133065610.SGD","LU0949170772.SGD","LU2517655374.HKD","LU1430594728.SGD","LU0198837287.USD","JDOC","LU1084165304.USD","LU0265550946.USD","SPAM","LU1496350502.SGD","BK4613","LU2125909593.SGD","FXL","LU1712237335.SGD","LU0234570918.USD","LU0310800965.SGD","IBB","LU2041044095.USD","LU0444973449.USD","LU1116320901.HKD","LU0154236417.USD","LU1670711123.USD","LU0965509010.AUD","LU1929549753.HKD","SG9999001176.USD","HCA","IE00BN8TJ469.HKD","LU0128525689.USD","LU0310800379.SGD","LU1923623000.USD","LU2087621335.USD","ADI","LU0726765562.USD","LU2360032135.SGD","IE00BZ199S13.USD","IE00B4R5TH58.HKD","XNTK","BK4007","LU1037948541.HKD","FTXL","LU0320765489.SGD","LU1244550221.USD","LU0820561909.HKD","IE0004445239.USD","LU1951200564.SGD","SG9999003800.SGD","SG9999014567.USD","BK4097","LU0211328371.USD","LU0029864427.USD","LU0320765646.SGD","LU0097036916.USD","IE00B775SV38.USD","LU1303367103.USD","LU2242652126.USD","IXJ","LU0690374961.EUR","BK4560","LU0265550359.USD","LU0957808578.USD","IE000SO60NU8.SGD","WCBR","BK4139","LU0553294199.USD","BK4515","GNOM","LU2129689605.HKD","LU1720051108.HKD","IE00B19Z3581.USD","BK4596","IE00BGHQF631.EUR","BK4116","LU2506951875.HKD","IE00BLSP4239.USD","LU1267930227.SGD","LU0170899867.USD","AIFD","SMHX","04332","SG9999014559.SGD","LU1923622291.USD","SG9999014575.USD","LU1066053197.SGD","LU0203347892.USD","LU2357627491.SGD","LU1093756325.SGD","BK4083","LU1923622614.USD","LU0433182093.SGD","LU1804176565.USD","AIS","LU1978683503.SGD","IE00BMPRXR70.SGD","LU0889565916.HKD","LU2250418816.HKD","CRWD","BK4094","BK4597","IE00B5TLWC47.USD","AGNG","LU1699723380.USD","TGT","LU0069063385.USD","LU1992135472.HKD","LU2506952097.USD","LU1061106388.HKD","LU2468319806.SGD","BK4551","LU1989764664.SGD","PCTY","LU1261432733.SGD","LU2552382132.HKD","LU0724618433.USD","BK4503","BK4141","LU0208291251.USD","LU1035773651.USD","LU1691799644.USD","LU0878866978.SGD","SG9999015358.SGD","LU0823421333.USD","DTCR","LU0985489474.SGD","LU0053666078.USD","PSWD","LU1989764748.USD","LU1670710588.SGD","LU1861215975.USD","LU0648001328.SGD","LU0114720955.EUR","LU2237443465.HKD","LU2275660780.HKD","QQQA","LU0312595415.SGD","LU1551013342.USD","IE00BVYPNW00.USD","LU0234572021.USD","GDOC","BK4512","IBBQ","IE00B42XCP33.USD","LU1150488135.SGD","LU1670627923.USD","LU2237443978.SGD","LU1201861249.SGD","IE00B894F039.SGD","LU0708994859.HKD","LU0203345920.USD","BK4155","BK4607","LU1066051811.HKD","BK4559","LU1674673691.USD","WUGI","LU2324357040.USD","LU2347655073.USD","LU1642822529.SGD","LU0056508442.USD","BK4543","LU0795875086.SGD","LU0823411888.USD","LU0823416689.USD","LU2473716301.USD","RXL","LU1489326972.SGD","BK4023","LU1670628061.USD","LU1951198990.SGD","LU0432979614.USD","IE00B3S45H60.SGD","LU2125154935.USD","LU0187121727.USD","LU2931357623.SGD","BK4554","LU2543165471.USD","LU1718418525.SGD","LU2125154778.USD","LU0109392836.USD","LU2089284900.SGD","LU0274383776.USD","CRWL","LU2089984988.USD","LU0124384867.USD","LU1732799900.SGD","LU0106261372.USD","LU1935043536.SGD","BK4532","LU0082616367.USD","LU2361045086.USD","LU0266013472.USD","LU0057025933.USD","WOLF","LU1069347547.HKD","LU1116320737.USD","LU1988902786.USD","LU2112291526.USD","LU0314106906.USD","LU0006306889.USD","LU1506573853.SGD","LU2272731782.SGD","DAT","LU1548497426.USD","LU1989773731.SGD","LU2322448957.HKD","LU1989772923.USD","LU0210528500.USD","BK4568","IHE","IE00BKVL7J92.USD","LU2491050154.USD","LU1670710661.SGD","LU2360108059.USD","LU1934455863.HKD","LU0472753341.HKD","LU0719512351.SGD","SG9999014013.SGD","AIPI","LU2347655156.SGD","PPH","LU0314104364.USD","LU2290526834.HKD","IE0002141913.USD","FTXH","BK4561","LU0786609619.USD","BK4183","AMGN","SOXY","IE00B19Z3B42.SGD","LU2491049909.HKD","LU2125909759.SGD","LU0942090050.USD","LU1119994496.HKD","BK4604","LU0980610538.SGD","IE00BZ1G4Q59.USD","BK4114","LU0738911758.USD","LU2237443622.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660473644","title":"福泰製藥(VRTX)股票8月19日收盤上漲4.48%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2660473644","media":"TradingKey中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660473644?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 04:16","pubTimestamp":1787170582,"startTime":"0","endTime":"0","summary":"• 在竞争对手临床试验宣告失败后，福泰制药股价飙升至历史新高。\n• 第二季度营收超出预期，公司同时上调了全年业绩指引。\n• 分析师纷纷给出看涨评级，平均目标价达 563.25 美元。","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262119125-market-movers-vrtx-20260819","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","LU2456880835.USD","BK4567","LU1674673428.USD","LU0079474960.USD","LU2462157665.USD","IBB","GNMX","SG9999001176.SGD","LU0320765992.SGD","LU0432979614.USD","BK4588","IBBQ","LU1778281490.HKD","LU2236285917.USD","LU2362541273.HKD","LU1585245621.USD","IE00B19Z3581.USD","LU0823416689.USD","LU0417517546.SGD","LU1069344957.HKD","IE00B4R5TH58.HKD","TBXU","LU0289739699.SGD","IDNA","VRTX","LU1674673691.USD","LU2362541513.USD","IE0002270589.USD","IE00B19Z9Z06.USD","LU0109394709.USD","LU2237438978.USD","BBH","PBE","BIB","LU0058720904.USD","IE00BFTCPJ56.SGD","LU2324357040.USD","LU0234570918.USD","IE00B19Z3B42.SGD","LU1093756325.SGD","SGXZ57979304.SGD","LU1035775433.USD","LU2468319806.SGD","LU0256863811.USD","BK4532","IE0009355771.USD","IE00B19Z9P08.USD","BK4139","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":187,"code":"91000000","status":"200"}]}}